PRECISION BIOTOOLS INC

Biotech · Private

T cell receptor mimic antibodies targeting KRAS mutation-associated neoantigens using Epivolve technology

Grants
$2.4M
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · A platform for T-cell receptor mimic antibody generation modeled using pHLA-A*11:01 KRAS G12D$1,221,746
Federal grantDepartment of Health and Human Services · Phase II · A platform for T-cell receptor mimic antibody generation modeled using pHLA-A*11:01 KRAS G12D$1,221,747
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3283Seranova Bio, Inc.—$15M
3284NUBAD LLC——
3285NANOMATRONIX LLC——
3286PRECISION BIOTOOLS INC——
3287Athletic DNA, Inc.—$4.2M
3288AMPLIFICA HOLDINGS GROUP, INC.—$28M
3289Exuma Biotech Corp.—$133M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.